1.6224
price up icon8.16%   0.1224
 
loading
Aprea Therapeutics Inc stock is traded at $1.6224, with a volume of 22,934. It is up +8.16% in the last 24 hours and down -28.21% over the past month. Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
See More
Previous Close:
$1.50
Open:
$1.55
24h Volume:
22,934
Relative Volume:
0.86
Market Cap:
$8.15M
Revenue:
-
Net Income/Loss:
$-14.29M
P/E Ratio:
-0.4066
EPS:
-3.99
Net Cash Flow:
$-12.27M
1W Performance:
+8.13%
1M Performance:
-28.21%
6M Performance:
-58.40%
1Y Performance:
-68.62%
1-Day Range:
Value
$1.51
$1.65
1-Week Range:
Value
$1.412
$1.65
52-Week Range:
Value
$1.412
$5.90

Aprea Therapeutics Inc Stock (APRE) Company Profile

Name
Name
Aprea Therapeutics Inc
Name
Phone
215-948-4119
Name
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Name
Employee
8
Name
Twitter
Name
Next Earnings Date
2024-12-07
Name
Latest SEC Filings
Name
APRE's Discussions on Twitter

Compare APRE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
APRE
Aprea Therapeutics Inc
1.6224 8.15M 0 -14.29M -12.27M -3.99
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.47 125.74B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
599.76 61.57B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
600.51 36.40B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.61 30.36B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
256.16 24.89B 3.81B -644.79M -669.77M -6.24

Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-28-20 Downgrade Robert W. Baird Outperform → Neutral
Dec-16-20 Initiated Berenberg Buy
Sep-29-20 Resumed JP Morgan Neutral
Jun-22-20 Initiated H.C. Wainwright Neutral
Apr-21-20 Initiated Robert W. Baird Outperform
Oct-28-19 Initiated JP Morgan Neutral
Oct-28-19 Initiated Morgan Stanley Equal-Weight
Oct-28-19 Initiated RBC Capital Mkts Outperform
View All

Aprea Therapeutics Inc Stock (APRE) Latest News

pulisher
Apr 17, 2025

Century Therapeutics Hosts Live Fireside Chat on Groundbreaking Cell Therapy Advances - MyChesCo

Apr 17, 2025
pulisher
Apr 17, 2025

APRE stock touches 52-week low at $1.5 amid market challenges - Investing.com Australia

Apr 17, 2025
pulisher
Apr 17, 2025

Adicet Bio Strengthens Board with Ex-Johnson & Johnson VP: Strategic Move for Cell Therapy Pioneer - Stock Titan

Apr 17, 2025
pulisher
Apr 10, 2025

Aprea Therapeutics Welcomes New Chief Medical Officer to Spearhead Clinical Pipeline Expansion - MSN

Apr 10, 2025
pulisher
Apr 10, 2025

Aprea Therapeutics Advances ACESOT-1051 Clinical Trial with Key Patient Dosing - MSN

Apr 10, 2025
pulisher
Apr 08, 2025

TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight - The Malaysian Reserve

Apr 08, 2025
pulisher
Apr 04, 2025

APRE stock touches 52-week low at $1.74 amid market challenges - Investing.com

Apr 04, 2025
pulisher
Apr 04, 2025

Aprea Therapeutics CEO Gilad Oren acquires $10,110 in stock By Investing.com - Investing.com India

Apr 04, 2025
pulisher
Apr 04, 2025

Aprea Therapeutics President/CEO Gilad Oren Acquires 5,500 Shares - TradingView

Apr 04, 2025
pulisher
Apr 04, 2025

Aprea Therapeutics CEO Gilad Oren acquires $10,110 in stock - Investing.com

Apr 04, 2025
pulisher
Apr 03, 2025

Biotech Alert: Searches spiking for these stocks today - TipRanks

Apr 03, 2025
pulisher
Apr 01, 2025

Aprea doses HPV+ HNSCC subject in cohort 5 of APR-1051 trial - Yahoo

Apr 01, 2025
pulisher
Apr 01, 2025

Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Up 28.0% in March - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 31, 2025
pulisher
Mar 30, 2025

What is Wedbush’s Estimate for APRE FY2025 Earnings? - The AM Reporter

Mar 30, 2025
pulisher
Mar 29, 2025

Brokers Issue Forecasts for APRE FY2025 Earnings - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

Aprea Therapeutics Reports 2024 Financial Results and Updates on Clinical Innovations - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

What is Wedbush’s Estimate for APRE FY2029 Earnings? - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

APRE stock touches 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

APRE stock touches 52-week low at $2.15 amid market challenges - Investing.com India

Mar 27, 2025
pulisher
Mar 26, 2025

Aprea Therapeutics (NASDAQ:APRE) Given “Outperform” Rating at Wedbush - Defense World

Mar 26, 2025
pulisher
Mar 26, 2025

Aprea Therapeutics Advances Cancer Trials Amid Financial Progress - TipRanks

Mar 26, 2025
pulisher
Mar 25, 2025

Aprea Therapeutics repots Q4 EPS (49c) vs. (92c) last year - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

Aprea Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 25, 2025
pulisher
Mar 25, 2025

APREA THERAPEUTICS Earnings Results: $APRE Reports Quarterly Earnings - Nasdaq

Mar 25, 2025
pulisher
Mar 25, 2025

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

Chronic Myeloid Leukemia Pipeline: Driving Innovation with 25+ - openPR.com

Mar 25, 2025
pulisher
Mar 21, 2025

Windtree Therapeutics and Evofem Announce Agreement to Lower Manufacturing Costs for PHEXXI - MyChesCo

Mar 21, 2025
pulisher
Mar 18, 2025

Mineralys Therapeutics to Present Phase 2 Advance-HTN Trial Data at ACC.25 - MyChesCo

Mar 18, 2025
pulisher
Mar 18, 2025

Aprea Therapeutics (APRE) Expected to Announce Quarterly Earnings on Tuesday - Defense World

Mar 18, 2025
pulisher
Mar 13, 2025

Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research - MyChesCo

Mar 13, 2025
pulisher
Mar 12, 2025

MD Anderson to explore Aprea’s WEE1 kinase inhibitor for HNSCC - BioWorld Online

Mar 12, 2025
pulisher
Mar 11, 2025

Aprea Therapeutics partners with MD Anderson for cancer study - Investing.com India

Mar 11, 2025
pulisher
Mar 11, 2025

Aprea Therapeutics Announces Agreement With MD Anderson Cancer Center To Explore Apr-1051 As A Potential Treatment For Head And Neck Squamous Cell Carcinoma (Hnscc) - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Aprea Therapeutics partners with MD Anderson for cancer study By Investing.com - Investing.com South Africa

Mar 11, 2025
pulisher
Mar 11, 2025

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC) - The Manila Times

Mar 11, 2025
pulisher
Mar 07, 2025

Aprea Therapeutics to Showcase Expertise at Maxim Healthcare Virtual Summit - MSN

Mar 07, 2025
pulisher
Mar 03, 2025

Aprea Therapeutics to Showcase Oncology Advances at Barcelona Symposium - MSN

Mar 03, 2025
pulisher
Feb 26, 2025

Head-To-Head Comparison: Apellis Pharmaceuticals (NASDAQ:APLS) versus Aprea Therapeutics (NASDAQ:APRE) - Defense World

Feb 26, 2025
pulisher
Feb 12, 2025

Insider Buyers Lose US$92k As Aprea Therapeutics Sheds US$3.2m - Simply Wall St

Feb 12, 2025
pulisher
Feb 07, 2025

Aprea Therapeutics Strengthens Patent Portfolio to Advance Oncology Innovation - MSN

Feb 07, 2025

Aprea Therapeutics Inc Stock (APRE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.54
price up icon 2.04%
$68.96
price down icon 2.60%
$32.03
price up icon 1.07%
$36.70
price up icon 10.44%
$120.54
price up icon 4.97%
biotechnology ONC
$256.16
price up icon 2.82%
Cap:     |  Volume (24h):